美国耐药性癫痫退伍军人与全体美国退伍军人及美国一般人群标准化死亡比的关联及医疗利用情况
这项观察性队列研究于2013年10月1日至2020年3月31日开展,比较美国耐药性癫痫退伍军人与美国一般人群及全体退伍军人的死亡率,并分析医疗利用与死亡率的关联。耐药性癫痫患者标准化死亡比分别为1.50和1.56,神经科门诊评估、脑电图、磁共振成像、癫痫监测及使用超过2种抗癫痫药物与较低死亡率相关。
要点
- 耐药性癫痫退伍军人标准化死亡比相较美国一般人群为1.50,相较全体退伍军人为1.56。
- 神经科门诊评估、脑电图、磁共振成像、癫痫监测及使用超过2种抗癫痫药物与较低死亡率相关。
- 仅15.0%的耐药性癫痫患者接受过全面癫痫评估,6.0%接受过癫痫监测。
核心结论
- 美国耐药性癫痫退伍军人的死亡率显著高于一般人群。
- 更充分地利用全面癫痫护理、诊断服务和药物均各自与死亡率降低相关。
- 这些发现表明,对耐药性癫痫进行适当管理对该人群至关重要。
研究设计与样本
- 观察性队列研究,于2013年10月1日至2020年3月31日开展。
- 在960万美国退伍军人中,164435人(1.7%)患有癫痫,其中55571人(33.8%)患有耐药性癫痫。
- 癫痫定义为使用1种或以上抗癫痫药物30天或更长时间并有癫痫发作诊断,或1次住院或2次门诊就诊有癫痫诊断;耐药性癫痫定义为使用2种或以上抗癫痫药物。
- 耐药性癫痫患者平均(标准差)年龄为58.3(15.4)岁,49430人(88.9%)为男性。
主要发现
- 耐药性癫痫退伍军人标准化死亡比相较美国一般人群为1.50(95% CI,1.47-1.53),相较全体退伍军人为1.56(95% CI,1.53-1.59)。
- 神经科门诊评估利用率为81.1%(n=45057),磁共振成像为66.4%(n=36905),脑电图检测为49.6%(n=27546)。
- 仅8350人(15.0%)接受过全面癫痫评估,3357人(6.0%)接受过癫痫监测。
- 多变量分析显示,在调整年龄和合并症后,神经科门诊评估、脑电图、磁共振成像、癫痫监测及使用超过2种抗癫痫药物与较低死亡率相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Drug-resistant epilepsy (DRE) is thought to be associated with increased mortality, but larger population-based studies are lacking. Additionally, the benefit of effective management in DRE lacks evidence. OBJECTIVE: To examine the association of utilization of care with mortality in US veterans with DRE. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study conducted between October 1, 2013, and March 31, 2020. Mortality statistics in US veterans with DRE were compared to the US general population and all veterans within the Veterans Health Administration. Epilepsy was defined as use of 1 or more antiseizure medications (ASMs) for 30 days or longer with a seizure diagnosis or 1 inpatient or 2 outpatient encounters with an epilepsy diagnosis. DRE was defined as the use of 2 or more ASMs. Among 9.6 million US veterans, 164 435 (1.7%) had epilepsy, of whom 55 571 (33.8%) had DRE. Epilepsy and DRE were administratively identified based on criteria noted in design. Identified participants were included for analysis. EXPOSURES: Veterans with DRE. MAIN OUTCOMES AND MEASURES: Standardized mortality ratio (SMR). RESULTS: Among US veterans with DRE, the mean (SD) age was 58.3 (15.4) years, and 49 430 individuals (88.9%) were male. Of ethnicity data gathered, 3170 individuals (5.7%) were Hispanic or Latino, 50 599 (91.1%) were not Hispanic or Latino, 842 (1.5%) declined to answer, and 960 (1.7%) were recorded as unknown. Of race data gathered, 516 individuals (0.9%) were American Indian or Alaskan Native, 270 (0.5%) were Asian, 11 316 (20.4%) were Black or African American, 587 (1.1%) were of multiple races, 453 (0.8%) were Native Hawaiian or Pacific Islander, 39 543 (71.2%) were White, 1697 (3.1%) declined to answer, and 1189 (2.1%) were recorded as unknown. SMR was 1.50 (95% CI, 1.47-1.53) compared with the US general population and 1.56 (95% CI, 1.53-1.59) compared with all veterans. Utilization rates were 81.1% (n = 45 057) for neurology clinic evaluation, 66.4% (n = 36 905) for magnetic resonance imaging (MRI), and 49.6% (n = 27 546) for electroencephalography (EEG) testing. Only 8350 individuals (15.0%) had comprehensive epilepsy evaluations and 3357 (6.0%) had epilepsy monitoring. Multivariable analysis revealed an association between lower mortality and neurology clinic evaluation, EEG, MRI, epilepsy monitoring, and the use of more than 2 ASMs after adjusting for age and comorbidities. CONCLUSIONS AND RELEVANCE: Mortality rates were significantly higher in US veterans with DRE compared to the general population. Better utilization of comprehensive epilepsy care, diagnostic services, and medications were each associated with reduced mortality. These findings indicate that appropriate management of DRE is critical in this population.
引用
- Haneef Z, Rehman R, Husain AM, et al. Association Between Standardized Mortality Ratio and Utilization of Care in US Veterans With Drug-Resistant Epilepsy Compared With All US Veterans and the US General Population. JAMA Neurol. 2022. PMID: 35969384. doi:10.1001/jamaneurol.2022.2290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。